1 of 1
Story summary
- In Q1 2026, Chinese biotech firms recorded US$60 billion in cross-border outlicensing, up 73% from 2025.
- The Q1 2026 total equals about half of 2025's US$135.7 billion in agreements, per the National Medical Products Administration.
- Outlicensing grants exclusive rights to develop and commercialize drugs after trials.
- Growth aligns with government innovation goals, and drugs are projected to grow 20% annually from 2026 to 2030, then 8.8% from 2030 to 2040.
